SCYNEXIS CEO to retire Dec 31; appoints new CEO David Angulo and CFO Ivor Macleod

SCYNEXIS INC

CEO Marco Taglietti to retire Dec 31, 2022; separation extends stock option exercise period to 4 years.
David Angulo (CMO) becomes President & CEO Jan 1, 2023; salary $565K, bonus 55%, option 165K shares, RSU 110K shares.
Ivor Macleod joins as CFO Oct 24, 2022; salary $435K, bonus 40%, option 170K shares, RSU 15K shares.
Interim CFO Larry Hoffman to step down; Chief Commercial Officer Christine Coyne to depart Nov 30, 2022.
Company to out-license BREXAFEMME, wind down promotion, focus ibrexafungerp on hospital indications.

item 1.02 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

David Angulo

President and Chief Executive Officer

SCYX · SCYNEXIS INC

Effective: 2023-01-01
Filed: October 20, 2022, 7:59 PM ET

On October 20, 2022, SCYNEXIS announced that David Angulo, M.D., SCYNEXIS’s Chief Medical Officer, will become SCYNEXIS’s President and Chief Executive Officer and become a member of the Board of Directors effective January 1, 2023.

Departed

Marco Taglietti

President and Chief Executive Officer

SCYX · SCYNEXIS INC

Effective: 2022-12-31
Successor: David Angulo
Filed: October 20, 2022, 7:59 PM ET

On October 14, 2022, Dr. Marco Taglietti announced to SCYNEXIS, Inc. that he plans to retire and will leave his position as President and Chief Executive Officer of SCYNEXIS, and will step down from the SCYNEXIS Board of Directors, on December 31, 2022.

Appointed

Ivor Macleod

Chief Financial Officer

SCYX · SCYNEXIS INC

Effective: 2022-10-24
Filed: October 20, 2022, 7:59 PM ET

On October 20, 2022, SCYNEXIS announced that Ivor Macleod, CPA, MBA, will become SCYNEXIS’s Chief Financial Officer, in which role he will become SCYNEXIS’s principal financial officer and principal accounting officer. Mr. Macleod’s anticipated first date of employment is October 24, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

David Angulo changed role as President and Chief Executive Officer at SCYNEXIS INC.

Action: become
Role: President and Chief Executive Officer

Exact text from the filing

On October 20, 2022, SCYNEXIS announced that David Angulo, M.D., SCYNEXIS’s Chief Medical Officer, will become SCYNEXIS’s President and Chief Executive Officer and become a member of the Board of Directors effective January 1, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Marco Taglietti departed as President and Chief Executive Officer at SCYNEXIS INC.

Action: retire
Role: President and Chief Executive Officer

Exact text from the filing

On October 14, 2022, Dr. Marco Taglietti announced to SCYNEXIS, Inc. that he plans to retire and will leave his position as President and Chief Executive Officer of SCYNEXIS, and will step down from the SCYNEXIS Board of Directors, on December 31, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Ivor Macleod was appointed as Chief Financial Officer at SCYNEXIS INC.

Action: become
Role: Chief Financial Officer

Exact text from the filing

On October 20, 2022, SCYNEXIS announced that Ivor Macleod, CPA, MBA, will become SCYNEXIS’s Chief Financial Officer, in which role he will become SCYNEXIS’s principal financial officer and principal accounting officer. Mr. Macleod’s anticipated first date of employment is October 24, 2022.

View on SEC.gov

SCYNEXIS INC filing history →

Source: SEC EDGAR

accession 0001564590-22-034777

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.